CompletedPhase 4

To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole

107 participantsStarted 2011-08

Plain-language summary

Administration of esomeprazole 20 mg to subjects who still had heartburn after receiving rabeprazole 10 mg once daily for at least 4 weeks will result in statistically significant improvement of heartburn after 8-week treatment.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male of female aged 20 years or more * History of reflux esophagitis * Ongoing (until date of Visit 1) treatment with rabeprazole 10 mg, given once daily, for at least 4 weeks.The subject must take rabeprazole at least 4 days a week in the past 7 days prior to Visit 1. * Persisting symptoms of heartburn experienced at least 2 days during the past 7 days prior to Visit 1. Exclusion Criteria: * Use of other PPIs and/or H2RA during rabeprazole treatment * History or having other gastrointestinal diseases * History of upper gastrointestinal surgery * Initiation of medications that can affect digestive functions within 4 weeks before study treatment * Inability to complete questionnaires

What they're measuring

Change in the Frequency of Heartburn During the 7-day Period Prior to the 8 Week Visit (Visit 3) Compared to the Frequency of Heartburn During the 7-day Period Prior to Baseline (Visit 1).

Timeframe: Baseline and 8 weeks

Trial details

NCT IDNCT01397084

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-01

Results submitted2013-01-16

View on ClinicalTrials.gov More Gastroesophageal Reflux Disease trials